PGHL · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 66/100 — Quality 88 · Valuation 31 · Momentum 75
| Share price | ₹6,852.50 |
| Market cap | ₹11,352 Cr |
| P/E ratio | 34.7 |
| P/B ratio | 21.6 |
| ROCE | 76.8% |
| Dividend yield | 1.36% |
| Book value | ₹316.00 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹1,408 Cr | ₹327 Cr | 30.8% |
| 2024 | ₹1,129 Cr | ₹201 Cr | 24.7% |
| 2023 | ₹1,206 Cr | ₹229 Cr | 24.5% |
| 2022 | ₹1,092 Cr | ₹193 Cr | 22.7% |
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble